Cytek Biosciences, Inc. 8-K

What Happened
Cytek Biosciences (CTKB) announced that Valerie Barnett’s role as Chief Legal Officer and Corporate Secretary terminated effective June 29, 2026. On July 9, 2026 (the Separation Date) the company and Ms. Barnett executed a severance agreement under which she provided a release of claims and will receive a one-time lump-sum payment and continued COBRA coverage. The parties also entered a consulting agreement effective July 10, 2026 for transition support.

Key Details

• Severance payment: one-time lump sum of $365,775.12.
• COBRA: company will pay COBRA premiums through the earlier of April 30, 2027, or until Ms. Barnett obtains other employer coverage.
• Change-in-control protection: if a Change in Control occurs within 3 months after the Separation Date, Ms. Barnett would instead be eligible for (a) 18 months of her base salary plus (b) an amount equal to her 2026 bonus target; any paid severance amount would be credited against those benefits. In that event, COBRA would be paid through January 31, 2028 and then-outstanding equity awards would fully accelerate and vest.
• Consulting: effective July 10, 2026, Ms. Barnett may provide transition services at $1,000/hr, up to 10 hours/week, initially through August 31, 2026; during this consulting term her previously granted equity awards will continue to vest subject to plan terms.

Why It Matters
This filing documents an executive departure and the related cash and potential contingent obligations. The immediate cash cost to the company is the stated severance payment and COBRA premiums; a near-term Change in Control could trigger larger cash payments and acceleration of equity awards, which would affect cash flows and could accelerate potential dilution from equity vesting. The consulting arrangement aims to preserve continuity during the transition. Full Severance and Consulting Agreements will be filed as exhibits to the company’s Form 10-Q for the quarter ended June 30, 2026.